Welcome to our dedicated page for HARTE HANKS SEC filings (Ticker: HHS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on HARTE HANKS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into HARTE HANKS's regulatory disclosures and financial reporting.
Harte Hanks, Inc. reports weaker 2025 revenue but a much smaller net loss. Operating revenue fell to $159.6 million, down 13.9% from $185.2 million in 2024, as demand softened, especially in Revenue Solutions.
Operating income dropped to $0.4 million from $2.1 million, cutting operating margin to 0.2% from 1.1%. Despite this, net loss narrowed sharply to $0.8 million from $30.3 million, mainly due to a steep decline in other expenses. The company continued its "Project Elevate" restructuring, targeting $16.0 million of cost reductions over 2024–2025 and recorded restructuring charges of $1.8 million in 2025 and $2.4 million in 2024.
Harte Hanks Inc. received an updated ownership report on its common stock from Westerly Capital Management, LLC and related parties on a Schedule 13G/A (Amendment No. 8).
The reporting persons state beneficial ownership of 627,000 shares of Harte Hanks common stock, representing 8.5% of the class, with shared voting and dispositive power over all of these shares and no sole voting or dispositive power. This percentage is calculated based on 7,414,794 shares outstanding as of October 31, 2025, as referenced from the company’s Form 10-Q for the quarter ended September 30, 2025. The filers certify the shares were not acquired or held for the purpose of changing or influencing control of Harte Hanks.
Harte Hanks Inc director Genevieve Combes reported an equity grant of company stock. On 12/09/2025 she was awarded 27,861 restricted stock unit (RSU) shares of common stock at $3.23 per share, scheduled to vest 100% on the first anniversary of the grant date.
After this award, she beneficially owns 26,283 common shares directly, plus 27,861 RSU shares from the 2025 grant, 12,048 RSU shares granted on 5/23/2024 that vested on 5/23/2025, and 16,216 RSU shares granted on 8/17/2023 that vested on 8/17/2024, with receipt of the vested RSU shares deferred until a later date.
Harte Hanks Inc. director Bradley Radoff reported receiving 27,861 shares of common stock as restricted stock units (RSUs) on 12/09/2025 at $3.23 per share. These RSUs will vest 100% on the first anniversary of the grant date.
After this grant, he beneficially owns 27,861 RSUs held indirectly, 391,399 shares of Harte Hanks common stock directly, 20,000 shares held indirectly in an IRA, and 12,048 additional shares held directly that vested 100% on 5/23/2025.
Harte Hanks (HHS) filed its Q3 2025 10‑Q, showing softer demand across all segments and a swing to loss. Revenue was $39.5M (down 17% year over year) with operating income of $0.5M versus $1.9M a year ago. After other expenses of $0.2M and income tax expense of $2.6M, the company reported a net loss of $2.3M (basic and diluted EPS $(0.31)).
By segment in Q3: Marketing Services $8.8M and Customer Care $11.6M declined on customer turnover and program timing, while Fulfillment & Logistics $19.1M delivered stronger profitability, lifting segment operating income to $1.7M from $1.1M last year. Year to date, revenue was $119.7M (down 13.3%) and operating income was $0.5M.
Cash and equivalents were $6.5M at September 30, 2025; net cash used in operating activities was $2.5M year to date. The company extended its $25.0M revolving credit facility to June 30, 2028 at SOFR + 2.25%, had $1.0M in letters of credit outstanding, and no borrowings, leaving $24.0M available capacity. Project Elevate restructuring costs were $0.5M in Q3 and $1.5M year to date; total targeted reorganization savings across 2024–2026 are $16.0M. Shares outstanding were 7,414,794 as of October 31, 2025.
Harte Hanks (HHS) furnished a press release announcing financial results for the third quarter ended September 30, 2025. The company provided the update under Item 2.02, and the release is included as Exhibit 99.1.
The information in Item 2.02, including Exhibit 99.1, is furnished and not deemed filed under the Exchange Act. Harte Hanks’ common stock trades on NASDAQ under the symbol HHS.
Harte Hanks reported lower revenue and a small net loss for the quarter ended June 30, 2025.
Revenue fell to $38.6 million for the quarter (down 14.2% year-over-year) and $80.2 million for the six months (down 11.4%). The company recorded a net loss of $0.3 million for the quarter and $0.7 million for six months, equal to basic and diluted losses per share of $0.05 and $0.10, respectively. Cash and cash equivalents declined to $4.8 million at June 30, 2025. Operating expenses declined year-over-year (11.6% for the quarter; 9.6% for six months) as the company reduced labor and other costs and continued its transformation program, Project Elevate, which targets $16.0 million of cumulative savings. The company extended its asset-based revolving Credit Facility to June 30, 2028 and had $24.0 million of borrowing availability after letters of credit.